Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
2021 · Leukemia · 109 citations
https://doi.org/10.1038/s41375-021-01125-4
D
Dan Zhao
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
402
Papers
7.0K
Citations
46
h-index
129
i10-index
Dan Zhao is an academic researcher from Qingdao University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Pancreatic and Hepatic Oncology Research & Cancer Genomics and Diagnostics. The author has an h-index of 46, co-authored 342 publications.
ORCID: 0000-0001-7066-9058Papers by this author
worksUltrasoft gelatin aerogels for oil contaminant removal
2016 · Journal of Materials Chemistry A · 99 citations
https://doi.org/10.1039/c6ta03146c
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
2024 · npj Precision Oncology · 75 citations
https://doi.org/10.1038/s41698-024-00505-0
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
2019 · Journal of Hematology & Oncology · 64 citations
https://doi.org/10.1186/s13045-019-0737-2
The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer
2017 · Scientific Reports · 57 citations
https://doi.org/10.1038/srep40374
Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors
2017 · PLoS ONE · 44 citations
https://doi.org/10.1371/journal.pone.0180541
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat